The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic value of the modified Glasgow Prognostic Score in patients with metastatic pancreatic cancer: An exploratory analysis of JCOG1611.
 
Taito Fukushima
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Takeda
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); MSD (Inst); SERVIER (Inst)
 
Satoshi Kobayashi
Honoraria - AstraZeneca; Chugai Pharma; Eisai; MSD; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Yakult Honsha
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Eisai (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Yuya Ishikawa
No Relationships to Disclose
 
Yusuke Sano
No Relationships to Disclose
 
Akihiro Ohba
Honoraria - AstraZeneca; Eisai; Guardant Health; MSD; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Zymeworks
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Hiroshi Imaoka
Honoraria - AstraZeneca; Boston Scientific; Kaneka Medix; Medico's Hirata; Novartis; SB-KAWASUMI LABORATORIES; SERVIER; Yakult Honsha
Consulting or Advisory Role - SERVIER
Research Funding - Boehringer Ingelheim (Inst); Grant from the National Cancer Center Research and Development Fund (Grant Number 2025-A-16) (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); SERVIER
Expert Testimony - Kaneka Medix
 
Yasuyuki Kawamoto
Honoraria - AstraZeneca; Incyte; Lilly Japan; Merck; MSD K.K; Nihon Servier; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Taiho Pharmaceutical
Research Funding - Japan Agency for Medical Research and Development; Takeda
 
Takuji Okusaka
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Johnson & Johnson/Janssen; Novartis; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; AstraZeneca; Eisai; Jazz Pharmaceuticals; Nihon Medi-Physics; Ohara Pharmaceutical
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience; Eisai (Inst); Incyte; LabCorp (Inst); Linical (Inst); Syneos Health/Immunocore (Inst); Sysmex (Inst)
 
Taro Yamashita
No Relationships to Disclose
 
Masafumi Ikeda
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; EA Pharma; Eisai; Exact Sciences; Guardant Health; Incyte; MSD; Nobelpharma; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Takeda; Teijin Pharma
Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Delta-Fly Pharma; Eisai; GlaxoSmithKline; Guardant Health; MSD; Nihon Medi-Physics; Novartis; Ono Yakuhin; Rakuten Medical Japan; Roche; SERVIER
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Eisai (Inst); InVitae (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); MSD (Inst); Nihon Servier (Inst); Novartis (Inst); Rakuten Medical Japan (Inst); Syneos Health (Inst)
 
Ichiro Yasuda
No Relationships to Disclose
 
Kentaro Yamazaki
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Taiho Pharmaceutical (Inst)
 
Ken Kamata
No Relationships to Disclose
 
Nao Fujimori
No Relationships to Disclose
 
Toshifumi Kin
No Relationships to Disclose
 
Kosuke Okuwaki
No Relationships to Disclose
 
Kazuhiko Shioji
No Relationships to Disclose
 
Masato Ozaka
Honoraria - AstraZeneca; Bayer; Eisai; MSD; Novartis; Ono Pharmaceutical; Pfizer; SERVIER; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Junji Furuse
Honoraria - Astellas Pharma; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; J-Pharma; MSD; Novartis; Ohara Pharmaceutical; SERVIER; Taiho Pharmaceutical; Takeda; Teijin Pharma
Consulting or Advisory Role - Astellas Pharma; Delta-Fly Pharma; Eisai; J-Pharma; OncoTherapy Science
 
Makoto Ueno
Honoraria - Asca; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Incyte; J-pharma; MSD; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Takeda; Viatris
Consulting or Advisory Role - Boehringer Ingelheim; Novocure
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); Incyte (Inst); J-pharma (Inst); Jazz Pharmaceuticals (Inst); MSD (Inst); Novartis (Inst); Novocure (Inst); Ono Pharmaceutical (Inst); Revolution Medicines (Inst); Taiho Pharmaceutical (Inst)